Weekly Research Analysts’ Ratings Changes for BlossomHill Therapeutics (BLSM)
Several brokerages have updated their recommendations and price targets on shares of BlossomHill Therapeutics (NASDAQ: BLSM) in the last few weeks: 9/2/2026 – BlossomHill Therapeutics was upgraded by Zacks Research to “hold”. 9/1/2026 – BlossomHill Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock. […]
18 Sep 14:56 · The Markets Daily